Translational studies of autoimmune-mediated lung disease

自身免疫介导的肺部疾病的转化研究

• 批准号: 8966038
• 负责人: Anthony Shum
• 金额: $ 38.46万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-12-01 至 2019-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8966038
• 关键词: Adoptive Transfer; Affect; Animal Model; Animals; Antigens; Asthma; Autoantibodies; Autoantigens; Autoimmune Diseases; Autoimmune Process; Autoimmune Responses; Autoimmunity; B-Lymphocyte Epitopes; B-Lymphocytes; Biological Assay; Cells; Cicatrix; Clinical; Complex; Connective Tissue Diseases; Data; Defect; Development; Diagnosis; Diagnostic; Disease; Disease Progression; Early Diagnosis; Early Intervention; Epitopes; Fibrosis; Genes; Goals; Health; Human; Immune; Immune Targeting; Immune Tolerance; Immune response; Inflammatory Response; Interferons; Interleukin-17; Interstitial Lung Diseases; Interstitial Pneumonia; Intervention; Kinetics; Knock-in; Lead; Link; Lung; Lung diseases; Maps; Mediating; Mediator of activation protein; Modeling; Monitor; Mus; Pathogenesis; Patient risk; Patient-Focused Outcomes; Patients; Peptide/MHC Complex; Peptides; Predisposition; Proteins; Pulmonary Fibrosis; Pulmonary Pathology; Reporter; Rheumatoid Arthritis; Role; Scleroderma; Self Tolerance; Sensitivity and Specificity; Staging; Syndrome; System; T cell response; T-Lymphocyte; T-Lymphocyte Epitopes; Th1 Cells; Time; Transgenic Mice; Translating; Work; autoreactive T cell; central tolerance; cytokine; disease diagnosis; improved; insight; lung development; lung injury; mortality; novel; patient subsets; prevent; response; risk variant; tool; translational study

DESCRIPTION (provided by applicant): Interstitial lung disease (ILD) is a complex and heterogeneous disorder that is often associated with autoimmune syndromes; however, despite the connection between ILD and autoimmunity, studies have yet to identify a pathogenic mechanism whereby an autoimmune response specifically targets the lung within ILD patients. With our discovery of novel mouse and human lung antigens (BPIFB1) targeted in autoimmune- mediated ILD, we have linked an autoimmune response to the lung-specific protein BPIFB1 and clinical ILD. Our studies in the Aire translational model have demonstrated a critical role for lun autoantigens in ILD pathogenesis. Patients with defects in the AIRE gene develop the human Autoimmune Polyglandular Syndrome Type 1 (APS1), which includes lung autoimmunity, due to a well-defined breakdown in immune tolerance. Importantly, lung autoimmunity in this model shows relevance to more common forms of autoimmune-associated ILD, as patients and mice with defects in Aire develop autoimmune ILD that is pathologically identical to the ILD of autoimmune connective tissue disorders such as in RA. Strikingly, a subset of non-APS1 patients with autoimmune ILD harbor autoantibodies to BPIFB1, the major human antigen we identified in our model. These results strongly suggest that the Aire model represents a novel ideal system for studying the role of lung-specific autoimmunity in ILD pathogenesis. We hypothesize that autoreactive T cell responses targeting self-antigens in the lung are an important mechanism for inciting interstitial lung inflammation and fibrosis in autoimmune disease. We aim to develop improved insights into disease mechanisms to allow targeted cytokine or cellular interventions in preventing lung autoimmunity and lung fibrosis. To this end we will: (1) define the role of BPIFB1 as a major lung autoantigen in lung autoimmunity; (2) define the role of TH17 cells in autoimmune lung fibrosis; and (3) develop tools for improved diagnosis and disease monitoring in ILD patients. With completion of the proposed studies, we will be poised to gain significant insight into the relevant antigenic targets and effector mechanisms of autoimmune-mediated ILD. By demonstrating that loss of self-tolerance to lung-specific antigens contributes to ILD in a subset of patients with known or unrecognized autoimmunity, we will establish the role of these mechanisms in autoimmune lung injury and progression to lung fibrosis. With development of sensitive and antigen-specific assays, we hope to more accurately diagnosis autoimmune-associated ILD at earlier stages, allowing at risk patients to be monitored or undergo more specific immune-targeted interventions to alter the devastating course of ILD and resultant lung fibrosis.

描述（由申请人提供）：间质性肺疾病（ILD）是一种复杂的异质性疾病，通常与自身免疫性综合征相关；然而，尽管ILD与自身免疫之间存在联系，但研究尚未确定ILD患者中自身免疫反应特异性靶向肺部的致病机制。随着我们发现新的小鼠和人肺抗原（BPIFB1）靶向自身免疫介导的ILD，我们已经将自身免疫反应与肺特异性蛋白BPIFB1和临床ILD联系起来。我们在Aire转化模型中的研究已经证明了lun自身抗原在ILD发病机制中的关键作用。AIRE基因缺陷的患者会发展为人类自身免疫性多腺综合征1型（APS1），其中包括肺自身免疫，这是由于免疫耐受的明确破坏。重要的是，该模型中的肺自身免疫显示出与更常见形式的自身免疫相关的ILD相关，因为Aire缺陷的患者和小鼠发展为自身免疫性ILD，其病理上与自身免疫性结缔组织疾病（如RA）的ILD相同。引人注目的是，非aps1患者中有一部分自身免疫性ILD患者携带BPIFB1的自身抗体，这是我们在模型中发现的主要人类抗原。这些结果强烈表明，Aire模型为研究肺特异性自身免疫在ILD发病机制中的作用提供了一个新的理想系统。我们假设，肺中针对自身抗原的自身反应性T细胞反应是自身免疫性疾病中激发间质性肺炎症和纤维化的重要机制。我们的目标是发展对疾病机制的更好见解，以允许靶向细胞因子或细胞干预预防肺自身免疫和肺纤维化。为此，我们将：(1)确定BPIFB1在肺自身免疫中作为主要肺自身抗原的作用；(2)明确TH17细胞在自身免疫性肺纤维化中的作用；(3)开发用于改善ILD患者诊断和疾病监测的工具。随着这些研究的完成，我们将对自身免疫介导的ILD的相关抗原靶点和效应机制有更深入的了解。通过证明在已知或未被识别的自身免疫患者中，对肺特异性抗原的自我耐受性的丧失有助于ILD的发生，我们将确定这些机制在自身免疫性肺损伤和肺纤维化进展中的作用。随着敏感性和抗原特异性检测的发展，我们希望在早期阶段更准确地诊断自身免疫相关的ILD，允许有风险的患者进行监测或进行更特异性的免疫靶向干预，以改变ILD的破坏性过程和由此产生的肺纤维化。